Ezetimibe for primary hypercholesterolaemia

Ezetimibe for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia (Single Technology Assessment for NICE)

Primary hypercholesterolaemia is a form of dyslipidemia characterised by abnormalities of lipoprotein transport associated with high concentrations of cholesterol in the blood. People with hypercholesterolaemia are at increased risk of cardiovascular disease (CVD) owing to the fact that long-term high concentrations of cholesterol are known to accelerate atherosclerosis, the build-up of fatty deposits in the arteries.

This project was carried out as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal Process. The company responsible for ezetimibe (Merck Sharp & Dohme Ltd) submitted an evidence review and an economic model assessing the cost-effectiveness of the drug, alone or in combination with statin treatment, against no treatment or statin alone for the treatment of primary hypercholesterolaemia. The Aberdeen HTA group were commissioned to act as the Evidence Review Group (ERG) for the project, and to provide an independent report reviewing the company’s evidence submission.

Outcome and Translation

Following consideration of the company submission and the ERG report, the NICE appraisal committee recommended ezetimibe as a treatment option for some people with heterozygous-familial and non-familial hypercholesterolaemia: http://www.nice.org.uk/guidance/ta385/chapter/1-Recommendations.

National Institute for Health and Care Excellence (2016) Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia, Technology Appraisal Guidance [TA385], London: NICE.

Publications

Scotland, G., Javanbakht, M., Scott, N., Cruickshank, M., Sharma, P., Fraser, C., Simpson, W. and Brazzelli, M. (2015) Ezetimibe for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia. Report from Aberdeen Health Technology Assessment Group to NICE Appraisal Committee.

Presentations

Scotland, G., Javanbakht, M., Brazzelli, M. and Simpson, W. (2015) 'Report of the Evidence Review Group onTechnology Appraisal TA385: ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia', National Institute for Health and Care Excellence (NICE) Appraisal Committee Meeting, Manchester, 22 September 2015.

Scotland, G., Javanbakht, M., Brazzelli, M. and Simpson, W. (2015) 'Report of the Evidence Review Group onTechnology Appraisal TA385: ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia', National Institute for Health and Care Excellence (NICE) Appraisal Committee Meeting, Manchester, 18 November 2015.